Clinical outcome after progressing to frontline and second-line Anti–PD-1/PD-L1 in advanced urothelial cancer

ConclusionsPatients progressing to frontline ICIs are at risk of early death, excluding them from experiencing potential benefit from chemotherapyPatient summaryOur analysis suggests that outcomes after failing immunotherapy are poor, particularly in UC patients who received no prior chemotherapy.
Source: European Urology - Category: Urology & Nephrology Source Type: research